Endpoints News
Tampa General sues Lilly Read in browser
Endpoints News
Thank you for reading, dupa dupackia!
basic
UPGRADE
M Tue W Th F
7 July, 2026
Endpoints 11 - Reserve Your Spot
The most differentiated science stays out of public view. This September, the Endpoints newsroom reveals the 11 private companies worth watching, live at the State Room in Boston. See the list first, reserve your spot and save with the early bird rate.
presented by GeneOnline
Hon­ey­bear Bio­sciences Bring­ing To­tal Funds Raised to $34 Mil­lion to Ac­cel­er­ate Lead Ra­dio­phar­ma­ceu­ti­cal Can­di­dates in­to Clin­i­cal Tri­al
top stories
1. Vertex's $10B Crinetics deal marks its clearest step yet toward biopharma's top ranks
2. Tampa General kicks off legal fight over Lilly's 340B restrictions
3. Vera's IgAN approval kicks off competition with Otsuka
4. Novartis, Vertex and Ipsen extend pharma's M&A spree after 45 first-half acquisitions
5. Hengrui, Kailera's GLP-1 pill posts encouraging efficacy but high side effect rates in late-stage China trials
6. Updated: Compass Pathways touts durability data for psilocybin drug in depression ahead of year-end filing
more stories
• 
Lydia Ramsey Pflanzer
.

Coming from my health tech background, I'm particularly intrigued to see Tampa General's lawsuit against Lilly over withheld 340B discounts. It's not often you see a health system go toe-to-toe with a pharmaceutical company. Read Nicole DeFeudis' breakdown of the case here.
.
Lydia Ramsey Pflanzer
Deputy Editor, Endpoints News
Image: Shutterstock
1
by Max Gelman

Ver­tex Phar­ma­ceu­ti­cal­s' $10 bil­lion ac­qui­si­tion of an en­docrinol­o­gy start­up rep­re­sents the com­pa­ny’s clear­est and bold­est step to­ward the up­per ech­e­lon of the bio­phar­ma in­dus­try.

Long...

Read the full story
2
by Nicole DeFeudis

Tam­pa Gen­er­al Hos­pi­tal sued Eli Lil­ly for halt­ing its 340B dis­counts, kick­ing off a broad­er fight over whether phar­ma­ceu­ti­cal com­pa­nies can con­di­tion drug dis­counts on...

Read the full story
Manufacturing Day 2026
A year into the tariff era, the biopharma industry has stopped bracing for impact — however manufacturing and supply chain leaders are still rewriting their plans on the fly. We’re bringing together the experts tracking what R&D logistics looks like today. Join us — find out what’s next.
3
by Nicole DeFeudis

Ve­ra Ther­a­peu­tics’ fu­sion pro­tein at­aci­cept got an ac­cel­er­at­ed ap­proval on Tues­day for a chron­ic au­toim­mune dis­ease that dam­ages the kid­neys.

The drug will be mar­ket­ed...

Read the full story
4
by Kyle LaHucik

Bio­phar­ma's M&A en­gine is revved up and shows no signs of cool­ing off.

Four com­pa­nies have an­nounced ac­qui­si­tions in the first six days of Ju­ly...

Read the full story
5
by Elizabeth Cairns

The GLP-1 pill be­ing de­vel­oped by Hen­grui Phar­ma and Kail­era Ther­a­peu­tics post­ed de­cent re­sults in two late-stage Chi­na-based tri­als — one in obe­si­ty and the...

Read the full story
Kabir Nath, Compass Pathways CEO
6